Edwards Lifesciences Corporation $EW Shares Acquired by J. Safra Sarasin Holding AG

J. Safra Sarasin Holding AG raised its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 139.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 32,466 shares of the medical research company’s stock after buying an additional 18,908 shares during the quarter. J. Safra Sarasin Holding AG’s holdings in Edwards Lifesciences were worth $2,768,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of EW. Fjarde AP Fonden Fourth Swedish National Pension Fund increased its stake in Edwards Lifesciences by 7.0% during the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock valued at $10,719,000 after purchasing an additional 9,069 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Edwards Lifesciences by 13.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock worth $6,706,000 after purchasing an additional 10,078 shares during the period. Washington Trust Advisors Inc. lifted its position in shares of Edwards Lifesciences by 15.6% in the 3rd quarter. Washington Trust Advisors Inc. now owns 130,587 shares of the medical research company’s stock worth $10,156,000 after buying an additional 17,625 shares during the last quarter. Atlantic Union Bankshares Corp lifted its position in shares of Edwards Lifesciences by 2,240.9% in the 3rd quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock worth $925,000 after buying an additional 11,384 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp boosted its holdings in shares of Edwards Lifesciences by 97.3% in the 2nd quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock valued at $3,481,000 after buying an additional 21,950 shares during the period. Institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on EW. Truist Financial set a $89.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Wednesday, February 11th. Evercore restated an “outperform” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a research note on Monday, January 5th. Canaccord Genuity Group set a $87.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a report on Wednesday, December 17th. Stifel Nicolaus set a $110.00 price target on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Finally, Royal Bank Of Canada raised their price target on Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday, December 5th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $96.14.

Edwards Lifesciences Trading Up 0.7%

Edwards Lifesciences stock opened at $80.07 on Wednesday. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $46.16 billion, a price-to-earnings ratio of 43.75, a PEG ratio of 2.07 and a beta of 0.93. The firm has a 50-day moving average price of $81.85 and a two-hundred day moving average price of $81.72.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The business had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The business’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period last year, the firm posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total transaction of $1,103,960.00. Following the transaction, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at approximately $3,371,239.08. This trade represents a 24.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of Edwards Lifesciences stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $85.93, for a total transaction of $974,446.20. Following the sale, the vice president owned 21,266 shares in the company, valued at approximately $1,827,387.38. This represents a 34.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 61,718 shares of company stock valued at $5,236,281 in the last quarter. Corporate insiders own 0.34% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.